Claim Missing Document
Check
Articles

Found 3 Documents
Search

Pengaruh Pemberian Deksametason Terhadap Kadar D Dimer Plasma pada Pasien Tumor Otak Agus Setiawan; Dwi Pudjonarko; Dodik Tugasworo
Medica Hospitalia : Journal of Clinical Medicine Vol. 3 No. 1 (2015): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (288.963 KB) | DOI: 10.36408/mhjcm.v3i1.205

Abstract

Latar belakang : Kanker meningkatkan risiko trombosis dan meningkatkan kadar D dimer melalui disfungsi endotelial akibat VEGF yang diproduksi sel kanker. Terapi deksametason memperbaiki sawar darah otak dengan menurunkan VEGF, sehingga mengurangi edema vasogenik. Deksametason diperkirakan dapat menurunkan kadar D dimer plasma pada pasien tumor otak. Penelitian ini bertujuan untuk menganalisis hubungan antara pemberian deksametason dengan kadar Ddimer plasma pasien tumor otak. Metode : Penelitian ini menggunakan model eksperimental kuasi terhadap 17 pasien tumor otak, yang direkrut secara konsekutif, dan tidak dalam kemoterapi atau radioterapi. Diagnosis tumor otak didasarkan pada CT sken kepala dan D dimer plasma diukur dengan ELISA (Sysmex). Seluruh pasien diberikan terapi deksametason, dan kadar D dimer diukur sebelum dan 4 hari setelah pengobatan deksametason. Uji t berpasangan digunakan untuk menguji perubahan kadar D dimer. Hasil : Responden penelitian ini adalah perempuan sebanyak 11 (64,7%) pasien, sedangkan laki-laki sebanyak 6 (35,3%) pasien, dan terbanyak berada kelompok usia 41-50 tahun sebanyak 9 (52,9%) orang. Keadaan hiperkoagulasi (peningkatan kadar D dimer >500 ng/ml) pada sebanyak 6 (35,3%) pasien. Kanker yang paling sering adalah meningioma sebanyak 10 (58,8%) pasien, diikuti oleh glioma sebanyak 4 (23,5%) pasien dan metastase otak pada 3 (17,6%) pasien. Tidak terdapat perbedaan pada kadar D Dimer plasma antara pra dan pasca terapi deksametason (p=0,658). Terdapat hubungan yang bermakna antara jenis tumor otak (intra dan extra-axial) terhadap perubahan kadar D dimer plasma (p=0,029). Simpulan : Pemberian deksametason pada pasien dengan tumor otak tidak mempengaruhi kadar D dimer plasma
The Double Inflammatory Burden: Red Cell Distribution Width as an Exploratory Biomarker for Functional Outcome in Ischemic Stroke with Comorbid Systemic Lupus Erythematosus Resita Indah Sukraputri; Endang Kustiowati; Hexanto Muhartomo; Dodik Tugasworo; Aris Catur Bintoro; Elta Diah Pasmanasari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 5 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i5.1594

Abstract

Background: Ischemic stroke in patients with systemic lupus erythematosus (SLE) presents a highly unique clinical phenotype characterized by amplified systemic inflammation, profound endothelial dysfunction, and a pervasive prothrombotic state. The combined, synergistic effect of this double inflammatory burden exacerbates acute neuronal injury and leads to significantly poorer clinical recovery. This study evaluated Red Cell Distribution Width (RDW), a widely available surrogate marker of systemic inflammation, oxidative stress, and impaired erythrocyte deformability, as a prognostic biomarker for functional outcomes in this specific, high-risk inflammatory phenotype. Methods: In this retrospective analytical pilot study, 34 adult patients diagnosed with acute ischemic stroke and comorbid SLE were analyzed. Admission RDW values, National Institutes of Health Stroke Scale (NIHSS) scores, and 90-day Modified Rankin Scale (mRS) scores were collected. A poor functional outcome was rigorously defined as an mRS score of 3–6. Statistical evaluation included Mann-Whitney U tests, Spearman rank correlation, receiver operating characteristic (ROC) curve analysis, and multivariable logistic regression to adjust for baseline neurological severity. Results: RDW demonstrated a statistically significant positive correlation with initial stroke severity (NIHSS; r = 0.397; p = 0.020) and 90-day functional disability (mRS; r = 0.711; p < 0.001). The median RDW was significantly higher in patients with poor outcomes compared to those with good outcomes (15.6% versus 13.4%, p < 0.001). ROC analysis yielded an excellent Area Under the Curve of 0.89 (p < 0.001) with an optimal predictive cut-off established at 13.75%. In multivariable analysis adjusting for baseline stroke severity, an admission RDW of 13.75% or higher remained a strongly associated factor for severe long-term disability (adjusted Odds Ratio: 14.82, 95% Confidence Interval: 1.95–112.45, p = 0.009). Conclusion: RDW is a promising, inexpensive, and universally available prognostic biomarker that demonstrates a strong association with severe functional disability in ischemic stroke patients with comorbid SLE, accurately reflecting the profound neurotoxic impact of the double inflammatory burden.
The Double Inflammatory Burden: Red Cell Distribution Width as an Exploratory Biomarker for Functional Outcome in Ischemic Stroke with Comorbid Systemic Lupus Erythematosus Resita Indah Sukraputri; Endang Kustiowati; Hexanto Muhartomo; Dodik Tugasworo; Aris Catur Bintoro; Elta Diah Pasmanasari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 5 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i5.1594

Abstract

Background: Ischemic stroke in patients with systemic lupus erythematosus (SLE) presents a highly unique clinical phenotype characterized by amplified systemic inflammation, profound endothelial dysfunction, and a pervasive prothrombotic state. The combined, synergistic effect of this double inflammatory burden exacerbates acute neuronal injury and leads to significantly poorer clinical recovery. This study evaluated Red Cell Distribution Width (RDW), a widely available surrogate marker of systemic inflammation, oxidative stress, and impaired erythrocyte deformability, as a prognostic biomarker for functional outcomes in this specific, high-risk inflammatory phenotype. Methods: In this retrospective analytical pilot study, 34 adult patients diagnosed with acute ischemic stroke and comorbid SLE were analyzed. Admission RDW values, National Institutes of Health Stroke Scale (NIHSS) scores, and 90-day Modified Rankin Scale (mRS) scores were collected. A poor functional outcome was rigorously defined as an mRS score of 3–6. Statistical evaluation included Mann-Whitney U tests, Spearman rank correlation, receiver operating characteristic (ROC) curve analysis, and multivariable logistic regression to adjust for baseline neurological severity. Results: RDW demonstrated a statistically significant positive correlation with initial stroke severity (NIHSS; r = 0.397; p = 0.020) and 90-day functional disability (mRS; r = 0.711; p < 0.001). The median RDW was significantly higher in patients with poor outcomes compared to those with good outcomes (15.6% versus 13.4%, p < 0.001). ROC analysis yielded an excellent Area Under the Curve of 0.89 (p < 0.001) with an optimal predictive cut-off established at 13.75%. In multivariable analysis adjusting for baseline stroke severity, an admission RDW of 13.75% or higher remained a strongly associated factor for severe long-term disability (adjusted Odds Ratio: 14.82, 95% Confidence Interval: 1.95–112.45, p = 0.009). Conclusion: RDW is a promising, inexpensive, and universally available prognostic biomarker that demonstrates a strong association with severe functional disability in ischemic stroke patients with comorbid SLE, accurately reflecting the profound neurotoxic impact of the double inflammatory burden.